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Abstract
HIV/AIDS has always been one of the most thoroughly global of diseases. In the era of widely available anti-
retroviral therapy (ART), it is also commonly recognised as a chronic disease that can be successfully managed on a
long-term basis. This article examines the chronic character of the HIV/AIDS pandemic and highlights some of the
changes we might expect to see at the global level as HIV is increasingly normalised as “just another chronic
disease”. The article also addresses the use of this language of chronicity to interpret the HIV/AIDS pandemic and
calls into question some of the consequences of an uncritical acceptance of concepts of chronicity.
Background
HIV/AIDS has always been one of the most thoroughly
global of diseases. From its still hazily understood emer-
gence as a zoonotic infection in colonial and post-colo-
nial West and Central Africa and the early moral panics
over a globe-trotting “Patient Zero” to the current situa-
tion of global pandemic, it has always been intimately
bound up in globalised structures and processes [1-3].
If HIV was global from its beginnings, it came to be
seen as chronic only shortly thereafter. In 1989, soon
after the development of the first anti-retroviral mono-
therapies to treat AIDS, Samuel Broder, head of the US
National Cancer Institute, famously asserted at an inter-
national AIDS conference that HIV should be consid-
ered to be a chronic illness and its treatment “should
follow the model of cancer”. The 1992 book AIDS: The
Making of a Chronic Disease [ 4 ]p r o v i d e da nh i s t o r i c a l
account of HIV activism, clinical treatment, and phar-
maceutical research in the 80s that transformed the dis-
ease from an acute and consistently fatal condition to
one that promised to be manageable over the long term
through drug therapy.
From this initial period of the first life-extending treat-
ments in the late 80s to the triple therapy cocktails of
the late 90s and now, in the era of large-scale, public-
sector ART programmes, HIV clinicians and activists
have consistently pushed for a recognition of HIV as
“just another chronic disease” [5]. These attempts to
characterise HIV as a chronic–and by implication, a
stable, manageable, even normal–infection, however,
have also always existed in tension with efforts to excep-
tionalise the epidemic. On the one hand, when treat-
ment became available, activists and clinicians sought to
convince patients that HIV was no longer a death sen-
tence. On the other hand, there was real resistance to
the normalisation implied in such comparisons with
chronic diseases like diabetes. There has been a consis-
tent push to maintain the special status of HIV as a
unique global health challenge even as its identity as a
chronic condition gains strength [6,7].
What does HIV/AIDS’ status as one of the most pro-
minent global and increasingly chronic diseases have to
tell us about the broader questions raised in this special
issue about the place of chronic diseases and the idea of
chronicity in global health? This article examines the
intersection of globalisation, the HIV/AIDS pandemic,
and the idea of chronicity. It highlights recent shifts in
the character of the global HIV/AIDS epidemic and asks
how its increasingly chronic nature might be changing
global understandings of and responses to the disease. It
also argues that conventional notions of chronicity are
often inadequate to capture the complexities of not only
HIV/AIDS but many of the other diseases routinely
interpreted as chronic as well.
How is the Global HIV Epidemic Changing?
For the last 30 years, the world’sr e s p o n s et oH I Vh a s
gone through a number of dramatic transformations
including the rise of global AIDS activism and institu-
tions, the development of effective anti-retroviral thera-
pies, and struggles against several varieties of AIDS
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recent developments in the global epidemic, however,
especially in those countries with the highest burden of
HIV, that are vital to understand.
Over the last ten years, in high-prevalence countries
like those in Southern Africa, increasing (and increas-
ingly visible) AIDS-related mortality, mass prevention
and education campaigns, political and community
mobilisation, and public-sector ART programs have
meant that HIV is increasingly normalised in some
important ways. Disclosure is still difficult but no longer
rare. Politicians increasingly address the disease openly
and even get tested in public. The notion of HIV infec-
tion as an automatic death sentence is weakening. This
isn’t to say that full normalisation has been achieved by
any means–only that the social forms and interpreta-
tions of the disease have changed significantly in recent
years.
While there is some evidence that HIV stigma is,
overall, on the decline [10], stigma is poorly theorised
and researched [11], making generalisations difficult. It
is also important to keep in mind that changes in stigma
have, and will continue to be, uneven and unpredictable.
It may, in some settings, unexpectedly increase, even in
the presence of accessible ART programs and commu-
nity mobilisation. It can also take many forms, with one
form of stigma fading as other, equally pernicious forms
emerge [12]. Stigma can also affect different groups, like
children or sex workers, in different ways [13] and
require different strategies and interventions [14].
There have been important changes in the public
health response to HIV as well. Shifts towards political
and financial investments in ART programmes and
health systems strengthening have meant that many
governments are now committing to the mainstreaming,
integration, and decentralisation of HIV care [15]. Not
surprisingly, this process has also been uneven. The
integration of HIV care into primary care services has
enjoyed a range of critical successes in countries as var-
ied as Brazil, the Dominican Republic and Zimbabwe,
but it has also put enormous strain of many of these
systems and exposed serious underlying weaknesses
[16]. One response has been to shift tasks and de-pro-
fessionalise HIV care by, for example, having nurses
initiate ART on their own, allowing lay counsellors to
do finger pricks as part of mass testing campaigns, and
asking community health workers to serve as the front
line of care provision. These changes reflect an increas-
ingly popular model of HIV care and support that
understands the disease as a long-term condition to be
managed as much in the family and community as in
the clinic [17,18].
Perhaps the most significant change, however, has
been the scaling up of the ART programs in public
sector health systems and the gradual but significant
closing of the “treatment gap”. In just one year, for
example, between 2008 and 2009, ART coverage
increased globally from 28% to 36% [19]. While still far
short of what is needed, universal access to ART pro-
mises to be the key element in building public and poli-
tical narratives that “things have changed”,t h a tH I Vi s
at least on its way to no longer being a fatal acute dis-
ease but instead a manageable, long-term condition
[20-22].
Thus, though HIV/AIDS was labelled a chronic dis-
ease as early as the late 1980s in the US, it has really
only been in the last few years that it has been possible
to use the language of chronicity to describe HIV in
those parts of the rest of the world that have been hard-
est hit. But how might the global understandings of and
responses to HIV change as a result of this growing
interpretation of the epidemic as a chronic global condi-
tion? Many of the dramatic developments in the earlier
h i s t o r yo ft h eH I Ve p i d e m i cw e r ed r i v e nb yaf o c u so n
HIV’s acuity rather than its chronicity–its initially slow
but consistently fatal progression, its remarkable ability
to evade anti-retroviral treatments and vaccines, the sig-
nificant stigma attached to it, and the scale of the epi-
demic. How will its emerging identity as a chronic
disease with treatment options that dramatically extend
life change how global actors understand and address
HIV?
What Will Chronicity Mean for the Global HIV Pandemic?
One thing is for certain: whether chronic or not, global
economic forces will continue to structure in many
ways the risks and vulnerabilities of people for HIV.
This is not to say that the macroeconomic forces aren’t
changing. The global financial crisis has, for example,
occasioned a certain degree of self-reflection and
response to instabilities and inequalities in the global
economic system. But the broad effects, both positive
and negative, of economic globalisation and liberalisa-
tion, will continue to be felt in terms of both who gets
infected and how those infected and affected by HIV are
able to cope with the disease.
The economic vulnerabilisation of people, however,
may also worsen as a result of the transformation of
HIV into a chronic disease. On one hand, ART allows
the most economically active portions of the population
to return to work and this should ease the burden of
coping with the disease. On the other hand, though,
adherence challenges, episodes of serious illness, trans-
action and opportunity costs related to lifelong treat-
ment, and the need for continued investment of public
resources to fund treatment programmes will all put
serious and sustained pressure on communities and
states alike [23-25].
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opment aid programmes will also face a number of new
challenges. One will simply be maintaining the political
support necessary for the scale of international funding
required to manage HIV as a chronic condition. The
recently stabilising incidence rates of HIV in Southern
Africa along with the global financial crisis have raised
intense concerns, for example, around the sustainability
of global and national-level financing for ART pro-
grammes and other HIV prevention, care and treatment
efforts [26-28]. On one hand, this outcry reflects a justi-
fiable demand to maintain HIV as a global health prior-
ity and raises reasonable concerns around the fickleness
of global health and development spending and the
importance of maintaining targeted support in particu-
larly vulnerable populations.
On the other hand, those who would critique the
“AIDS industry” and the vested interests and habits of
thinking that surround the disease do–conspiracy the-
ories aside–have a point. Global funding for HIV has
risen, for example, from around $300 million in 1996 to
$13.7 billion as of 2009 [29], a massive increase but one
that is still short of the real need. While this funding
increase for HIV has taken place during a period of dra-
matic increases in global health and development fund-
ing overall, it remains the case that far more of this
money is available for HIV than any other health condi-
tion [30]. The recent attention paid by the WHO to the
neglect of non-communicable diseases (NCDs), for
example, has cast current levels of HIV funding in stark
contrast to NCDs which cause 80% of the deaths in
developing countries but receive only 3% of global
health development money [31].
The transformation of HIV into a chronic epidemic
will thus entail both increased HIV-specific funding
needs (especially as total treatment burdens increase
and battles over intellectual property rights to second-
and third-line treatment continue) as well as pressure to
dislodge some of the institutional agendas, relationships,
and resources that currently coalesce around the
epidemic.
Debates around health funding involve not only ques-
tions of which diseases should get what money; they
also ask whether disease-based funding is the best way
to spend the money. There are already intense debates
around the best forms of health development financing
in an era of large-scale ART. The often polarised
debates around verticalised programming versus hori-
zontal programming and health systems strengthening
will hopefully develop into more nuanced debates
around, for example, “diagonal” approaches that both
strike a balance between disease and systems priorities
as well as use disease-specific interventions to leverage
improvements in the broader health systems [32,33].
While some have cautioned that stripping HIV of its
exceptional status will reverse the gains already secured
[34], the integration of HIV services–along with the les-
sons of innovative HIV service delivery models–into
other chronic and primary health care services has
rightly been identified as a way to “jumpstart” improve-
ments in the broader health system [35].
This integration also presents an important opportu-
nity for AIDS activists to develop their strategies and
join forces with the emerging political interest in the
problems of NCDs and health systems. Working
together, activists would be in a better position to push
for long-term, sustained reform in health systems. Many
are caught, however, within an increasingly competitive
funding environment that still tends to reward those
diseases that achieve the most visibility and urgency on
the global scene, a dynamic that runs counter to equally
important activist efforts to normalise HIV as a chronic
disease.
There have been some interesting examples of NGOs
and social movements working successfully across dis-
ease categories, addressing broader issues of health
rights and social justice, and highlighting the social
determinants of health. Social movements in South
Africa like the Treatment Action Campaign (TAC) have
been seeking out new territory and strategies in trying
to determine what health activism will look like after
widespread ART is available [36]. However, there
haven’t been many examples yet of AIDS activists join-
ing together with others health activists groups and
agendas. How HIV/health activism refigures and sus-
tains itself in the face of widespread treatment is one of
the most interesting questions about the current state of
affairs.
For national health systems, thinking about HIV as a
chronic condition entails a number of potentially dra-
matic changes. Some of the changes will be driven sim-
ply by scale. Closing the treatment gap described above
will entail rapidly rising costs, not only for treatment
but for diagnostic and monitoring tests, for counsellors,
social workers and community health workers, for
health information systems, and for health system infra-
structure. These increases are, of course, in the context
of competing health priorities (chronic and otherwise)
and a likely persisting global economic malaise.
These changes will entail not only increases in the
total amount of resources allocated to HIV but also to
the organisation of the health system itself. Some form
of integration and decentralisation of ART pro-
grammes, and HIV care more generally, will be neces-
sary in many contexts. The scale of the necessary
reorganisation and integration of health care services is
potentially unprecedented, especially in the highest
prevalence countries.
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large-scale, public sector programs. Complexity will also
increase as the number of patients in long-term treat-
ment increases. These complexities will be seen in long-
term adherence challenges, resistance and treatment fail-
ures; co-morbidities with other conditions like diabetes,
TB, cancer and dementia; and the intended and unin-
tended interactions between treatment and prevention
efforts [37,38]. While HIV may, therefore, fit the broad
model of a chronic disease, it may also prove to be
more complicated to prevent and treat than many other
chronic diseases.
For those countries with smaller-scale epidemics and/
or access to sufficient resources, many of these chal-
lenges can be addressed independently, at the national
level. But for those countries without the resources to
fully manage their epidemics, their choices will continue
to be shaped by the broad range of global actors in HIV
on whose support they will continue to rely as much as
it will be by local contexts and resources [34]. Policy-
making and decisions around health and development
spending at the global level will therefore continue to
have a powerful influence on how these countries are
able to manage their epidemics.
What Is Problematic About the Concept of Chronicity?
While the concept of chronicity has been productively
used to describe and predict some of the recent trans-
formations in the HIV epidemic, it is also not without
i t sp r o b l e m sa sac o n c e p t u a lf r a m e w o r k .M a n yo ft h e
conventional understandings of “chronic” disease–as dis-
eases that are stable, manageable, and lifelong, as condi-
t i o n st h a ta r ei n v i s i b l eo ra tl e a s tw i t h o u tt h eu s u a l
acute signs, and as disorders linked to individual “life-
styles” and “behaviours"–do not adequately capture life
with HIV for most people.
The critique and extension of the concept of the
“chronic” is an area of active research in medical
anthropology and elsewhere. The simple conceptual dif-
ficulties of maintaining the common acute-versus-
chronic disease dichotomy (and the closely related infec-
tious versus non-communicable disease distinction) have
been well established in the early analyses of chronicity
and acuity [39]. More recently though, this dichotomy
has come under pressure for the ways it promotes an
unrealistic, and indeed dangerous image of these dis-
eases as stable, uniform, associated with “development”
and old age, and manageable through simple technical
interventions and individual agency (read compliance).
Consider, for example, the common narrative among
activists, clinicians, public health researchers, and espe-
cially those infected with HIV, that anti-retroviral ther-
apy has meant a singular resurrection from “near death”
to “new life”. These treatment narratives describe a
dramatic transition from a state of personal, existential
emergency to a state of good health and social reinte-
gration, one where those with HIV aren’t any different
than anyone else [40,41]. Indeed, ART, for those who
can get it and stay on it, can mean a radical transforma-
tion in the meaning and experience of HIV infection.
And the expansion of public ART programmes repre-
sents a dramatic, qualitative shift in the epidemic. These
treatment narratives have been critical in many coun-
tries in overcoming powerful denial and disbelief about
the effectiveness of ARVs. AIDS activism has won a sig-
nificant victory in this context in changing public opi-
nion and state policies and securing dramatic gains in
population health that ten years earlier seemed
impossible.
However, it is also true that the conventional narra-
tives of what acute and what chronic mean are inade-
quate for capturing these transformations, even under
the best of circumstances. The narratives of chronic
HIV infection and treatment described above centre on
an image of either a resurrected body (the “Lazarus
effect” of ART) or a vibrant, healthy body that never
had to be resurrected (because of early treatment), a
body that is strong and newly disciplined in maintaining
treatment and lifestyle adherence, newly normalised as
the sufferer, like billions of other people on the planet,
of just another chronic condition with no specified
endpoint.
What this narrative leaves out, however, are the some-
times dramatic fluctuations in health that characterise
most chronic illnesses (and especially HIV). It ignores
the fact that most chronic diseases are socially expected
to be invisible and manageable and those who aren’t
seen to thrive sufficiently are stigmatised for this failure
(the so-called “John Wayne” model of chronic disease
[42]). It makes invisible the short and long-term physical
toll and side effects of treatment and the considerable
difficulty of maintaining adequate supplies and precise
daily dosing of medication over the course of a lifetime
that will for many also include unemployment, trauma,
depression, and migration. Finally, treatment narratives
that celebrate HIV’s long-awaited arrival as a chronic
condition mask the persistence of the local and global
structural conditions that produced vulnerability and
infection in the past and continued suffering and poor
therapeutic adherence in the present.
I nt h ee n d ,t h o s ew h o s ec o u r s eo fi l l n e s sd o e s n ’tf i t
the model of stable, manageable, invisible chronic illness
may come to be seen–by communities and by the health
systems they rely on–either as “defaulters” or as unfor-
tunate statistical outliers. And ART programmes grow,
the number of people whose experiences of long-term
treatment do not match with these high expectations
will only increase.
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a powerful constraint to our understanding of how HIV
illness is produced, experienced and transformed. And
this matters not only for individual experiences and
interpretations of the disease. If used simplistically as a
guiding conceptual framework for global health policy
and programming around HIV, the idea of chronicity
could prove similarly short-sighted and damaging. Just
as HIV helped to catalyze a number of significant scien-
tific, policy, and political developments beyond the epi-
demic itself, we should be using the opportunity of this
latest phase of the epidemic to inspire shifts in our
broader understandings of what “chronicity” means and
how we should respond to it.
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